Connect with us
Ozempic, manufactured by Novo Nordisk, gains EMA approval for chronic kidney disease, reducing disease progression by 24%, per the Flow trial. With 40% of type 2...
The biosimilars market is poised for growth driven by increased R&D investment, favorable regulations, and strategic industry partnerships. Key opportunities arise from the expiration of patents...
In the first half of the year, Novo Nordisk saw significant growth in sales, with Ozempic revenue up 36% to 56.685 billion crowns (€7.596 billion) and...
Until now, in the field of anti-obesity treatments, there was a drug that attracted attention: Ozempic. It is also made by Novo Nordisk and is very...
The demand for products indicated against diabetes has increased. Large groups in the sector announced new investment plans to grow in this segment. However, not everything...
Novo Nordisk plans a €2.1 billion investment to strengthen its presence in France's industrial sector, according to French President. The biotech company aims to expand the...
More than half of the population of the countries of the Organization for Economic Cooperation and Development (OECD) was overweight or obese, according to the latest...